Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Sympo
 

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

More...